唐氏综合征创新疗法:T21研究学会国际虚拟会议。

IF 0.9 4区 医学 Q4 GENETICS & HEREDITY Molecular Syndromology Pub Date : 2023-04-01 Epub Date: 2022-11-11 DOI:10.1159/000526021
Eric D Hamlett, Lisi Flores-Aguilar, Benjamin Handen, Marie-Claude Potier, Ann-Charlotte Granholm, Stephanie Sherman, Victoria Puig, Jonathan D Santoro, María Carmona-Iragui, Anne-Sophie Rebillat, Elizabeth Head, André Strydom, Jorge Busciglio
{"title":"唐氏综合征创新疗法:T21研究学会国际虚拟会议。","authors":"Eric D Hamlett,&nbsp;Lisi Flores-Aguilar,&nbsp;Benjamin Handen,&nbsp;Marie-Claude Potier,&nbsp;Ann-Charlotte Granholm,&nbsp;Stephanie Sherman,&nbsp;Victoria Puig,&nbsp;Jonathan D Santoro,&nbsp;María Carmona-Iragui,&nbsp;Anne-Sophie Rebillat,&nbsp;Elizabeth Head,&nbsp;André Strydom,&nbsp;Jorge Busciglio","doi":"10.1159/000526021","DOIUrl":null,"url":null,"abstract":"<p><p>Research focused on Down syndrome continued to gain momentum in the last several years and is advancing our understanding of how trisomy 21 (T21) modifies molecular and cellular processes. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. During the COVID pandemic, T21RS held its first virtual conference program, sponsored by the University of California at Irvine, on June 8-10, 2021 and brought together 342 scientists, families, and industry representatives from over 25 countries to share the latest discoveries on underlying cellular and molecular mechanisms of T21, cognitive and behavioral changes, and comorbidities associated with Down syndrome, including Alzheimer's disease and Regression Disorder. Presentations of 91 cutting-edge abstracts reflecting neuroscience, neurology, model systems, psychology, biomarkers, and molecular and pharmacological therapeutic approaches demonstrate the compelling interest and continuing advancement toward innovating biomarkers and therapies aimed at ameliorating health conditions associated with T21.</p>","PeriodicalId":48566,"journal":{"name":"Molecular Syndromology","volume":"14 2","pages":"89-100"},"PeriodicalIF":0.9000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/ae/msy-0014-0089.PMC10090974.pdf","citationCount":"0","resultStr":"{\"title\":\"Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society.\",\"authors\":\"Eric D Hamlett,&nbsp;Lisi Flores-Aguilar,&nbsp;Benjamin Handen,&nbsp;Marie-Claude Potier,&nbsp;Ann-Charlotte Granholm,&nbsp;Stephanie Sherman,&nbsp;Victoria Puig,&nbsp;Jonathan D Santoro,&nbsp;María Carmona-Iragui,&nbsp;Anne-Sophie Rebillat,&nbsp;Elizabeth Head,&nbsp;André Strydom,&nbsp;Jorge Busciglio\",\"doi\":\"10.1159/000526021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Research focused on Down syndrome continued to gain momentum in the last several years and is advancing our understanding of how trisomy 21 (T21) modifies molecular and cellular processes. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. During the COVID pandemic, T21RS held its first virtual conference program, sponsored by the University of California at Irvine, on June 8-10, 2021 and brought together 342 scientists, families, and industry representatives from over 25 countries to share the latest discoveries on underlying cellular and molecular mechanisms of T21, cognitive and behavioral changes, and comorbidities associated with Down syndrome, including Alzheimer's disease and Regression Disorder. Presentations of 91 cutting-edge abstracts reflecting neuroscience, neurology, model systems, psychology, biomarkers, and molecular and pharmacological therapeutic approaches demonstrate the compelling interest and continuing advancement toward innovating biomarkers and therapies aimed at ameliorating health conditions associated with T21.</p>\",\"PeriodicalId\":48566,\"journal\":{\"name\":\"Molecular Syndromology\",\"volume\":\"14 2\",\"pages\":\"89-100\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/ae/msy-0014-0089.PMC10090974.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Syndromology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000526021\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/11/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Syndromology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000526021","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/11/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

摘要

在过去几年中,专注于唐氏综合征的研究继续取得进展,并推动了我们对21三体(T21)如何改变分子和细胞过程的理解。21三体研究学会(T21RS)是研究唐氏综合症的研究人员和临床医生的首要科学组织。在新冠肺炎疫情期间,T21RS于2021年6月8日至10日举行了由加州大学欧文分校赞助的第一个虚拟会议项目,来自25个国家的342名科学家、家庭和行业代表齐聚一堂,分享T21潜在细胞和分子机制、认知和行为变化的最新发现,以及与唐氏综合症相关的合并症,包括阿尔茨海默病和回归障碍。91篇反映神经科学、神经病学、模型系统、心理学、生物标志物以及分子和药理学治疗方法的前沿摘要展示了人们对创新旨在改善T21相关健康状况的生物标志物和疗法的强烈兴趣和持续进步。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society.

Research focused on Down syndrome continued to gain momentum in the last several years and is advancing our understanding of how trisomy 21 (T21) modifies molecular and cellular processes. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. During the COVID pandemic, T21RS held its first virtual conference program, sponsored by the University of California at Irvine, on June 8-10, 2021 and brought together 342 scientists, families, and industry representatives from over 25 countries to share the latest discoveries on underlying cellular and molecular mechanisms of T21, cognitive and behavioral changes, and comorbidities associated with Down syndrome, including Alzheimer's disease and Regression Disorder. Presentations of 91 cutting-edge abstracts reflecting neuroscience, neurology, model systems, psychology, biomarkers, and molecular and pharmacological therapeutic approaches demonstrate the compelling interest and continuing advancement toward innovating biomarkers and therapies aimed at ameliorating health conditions associated with T21.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molecular Syndromology
Molecular Syndromology Biochemistry, Genetics and Molecular Biology-Genetics
CiteScore
1.70
自引率
9.10%
发文量
67
期刊介绍: ''Molecular Syndromology'' publishes high-quality research articles, short reports and reviews on common and rare genetic syndromes, aiming to increase clinical understanding through molecular insights. Topics of particular interest are the molecular basis of genetic syndromes, genotype-phenotype correlation, natural history, strategies in disease management and novel therapeutic approaches based on molecular findings. Research on model systems is also welcome, especially when it is obviously relevant to human genetics. With high-quality reviews on current topics the journal aims to facilitate translation of research findings to a clinical setting while also stimulating further research on clinically relevant questions. The journal targets not only medical geneticists and basic biomedical researchers, but also clinicians dealing with genetic syndromes. With four Associate Editors from three continents and a broad international Editorial Board the journal welcomes submissions covering the latest research from around the world.
期刊最新文献
Biallelic Deletion of PEX26 Exon 4 in a Boy with Phenotypic Features of both Zellweger Syndrome and Infantile Refsum Disease. Is 5-Oxoprolinase Deficiency More than Just a Benign Condition? Clinical and Molecular Characterization of Mucopolysaccharidosis Type 3A and 3B in a Turkish Series. A Long-Term Follow-Up of a Patient with a Novel PORCN Variant and Additional Clinical Features Novel Mutation in the HSD17B10 Gene Accompanied by Dysmorphic Findings in Female Patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1